ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM) (SelNac)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02505087
Recruitment Status : Recruiting
First Posted : July 22, 2015
Last Update Posted : November 21, 2016
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The objective of this study is to determine whether the administration of N-acetylcysteine (NAC) improves oxidative stress. To determine this, the study will assess the impact of oral treatment on the balance between reduced and oxidized form of glutathione in erythrocytes of peripheral blood.

Condition or disease Intervention/treatment Phase
Selenoprotein N-related Myopathy Drug: N-Acetylcysteine followed by Placebo Drug: Placebo followed by N-Acetylcysteine Phase 2 Phase 3

Detailed Description:

A prospective, monocentric, crossover, double-blind, placebo-controlled study.

For each patient the study will be divided in two treatment periods of 6 months separated by a 2 month washout period. 24 patients will be randomized in two groups, one group treated first with placebo during 6 months, followed by 6 months; the second group treated in the reverse sequence, then placebo.

24 healthy volunteers will also be enrolled in the study in order to collect reference values for biochemical biomarkers.

D-1: run-up visit, patients will be hospitalized in intensive care unit to collect information about diet, physical activity and smoking.

During follow-up visits: we will analyze the impact of treatment with N-acetylcysteine (NAC) on:

  • Biomarkers of redox homeostasis,
  • Measures of locomotor functional capacity,
  • Body mass composition,
  • Respiratory functional abilities.

Biomarkers that reflect the status of antioxidant defense mechanisms, parameters that reflect the cell damage to oxidative stress, the markers of inflammation and metabolic alterations induced by oxidative stress, body composition in terms of lean mass and fat mass, the motor functional abilities, respiratory function capabilities, will be compare before and after treatment.

These measures could complement the information on the status of oxidative stress and clarify the effects of N-acetylcysteine (NAC) on the evolution of the disease in these patients.

The correlation of biomarker measurements in muscle and systemic tissues will be checked.

Furthermore we will collect information about the lifestyle through standardized questionnaires that include diet, smoking, and habitual physical activity. Environmental factors and lifestyle can influence the balance oxidant / antioxidant patients and contribute to the variability of the clinical severity of the disease.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pharmacological Treatment of a Rare Genetic Disease: Pilot Trial Phase II-III With N-acetylcysteine in Myopathy Associated SEPN1-RM (Selenoprotein N-related Myopathy)
Study Start Date : September 2015
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : November 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Muscle Disorders

Arm Intervention/treatment
Active Comparator: Placebo followed by N-Acetylcysteine
Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
Drug: Placebo followed by N-Acetylcysteine
Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.

Experimental: N-Acetylcysteine followed by Placebo
Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
Drug: N-Acetylcysteine followed by Placebo

Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.

Treatment periods are separated by a 2 month washout.


No Intervention: Healthy volunteers
The purpose of this group is to collect reference values for biochemical markers.



Primary Outcome Measures :
  1. Ratio of reduced glutathione and oxidized glutathione in blood erythrocytes. [ Time Frame: 6 months in each period ]

Secondary Outcome Measures :
  1. measure of health status according The 36-Item Short Form Health Survey (SF36) [ Time Frame: 6 months in each crossover period ]
  2. Evaluate the impact of fatigue according the Fatigue Severity Scale (FSS) [ Time Frame: 6 months in each crossover period ]
  3. Measurement of biomarkers in blood samples, muscle and fibroblasts [ Time Frame: 6 months in each crossover period ]
  4. Measure of Activity Limitation (Activlim test) [ Time Frame: 6 months in each crossover period ]
  5. Running speed measured by the test of 10 m [ Time Frame: 6 months in each crossover period ]
  6. Measures of motor function according a Motor Function Measure scale (MFM ) [ Time Frame: 6 months in each crossover period ]
  7. Muscular endurance is measured by the test of 2 minutes walk [ Time Frame: 6 months in each crossover period ]
  8. Measurement of the maximum voluntary contraction of the quadriceps [ Time Frame: 6 months in each crossover period ]
  9. The measurement of the endurance of the quadriceps [ Time Frame: 6 months in each crossover period ]
  10. Assessment of dyspnea according Borg scale [ Time Frame: 6 months in each crossover period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. For patients:

    • Patient >18 and <60 years old
    • Patients with Selenoprotein N-related myopathy with homozygous or compound heterozygous mutations in the gene SEPN1-RM
    • Informed written consent
    • Patients capable of being followed up throughout the duration of the study
    • Patient trained in the use of cough assist
    • Patients having an health insurance
    • Patient accepting to commit not to introduce major changes in diet and lifestyle during the study period
  2. For healthy volunteers:

    • volunteers >18 and <60 years old
    • Informed written consent
    • Health insurance

Exclusion Criteria:

  1. For patients:

    • Pregnancy
    • Intolerance to N-acetylcysteine (NAC), galactose or fructose; malabsorption glucose or galactose; lactase deficiency
    • Consumption of synthetic vitamins, NAC and other antioxidants within 3 months prior to inclusion
    • Treatment with corticosteroids or non-steroidal anti-inflammatory from time to time in the 4 weeks preceding the inclusion or for more than 3 days between 12 and 4 weeks before inclusion
    • Planned surgery within 3 months before inclusion or during the inclusion period
    • Intercurrent or existing illnesses such as chronic infectious diseases (HIV, hepatitis, etc.), asthma, malignant tumor pathology, Hematological Pathology
    • Expected survival less than 14 months
    • Inability to understand the instructions or the implications of the Protocol
  2. For healthy volunteers:

    • Pregnancy
    • Consumption of synthetic vitamins, NAC and other antioxidants within 3 months prior to inclusion
    • Treatment with corticosteroids or non-steroidal anti-inflammatory from time to time in the 4 weeks preceding the inclusion or for more than 3 days between 12 and 4 weeks before inclusion
    • Planned surgery within 3 months before inclusion or during the inclusion period
    • Intercurrent or existing illnesses such as chronic infectious diseases (HIV, hepatitis, etc.), asthma, malignant tumor pathology, Hematological Pathology
    • Inability to understand the instructions or the implications of the Protocol
    • Bleeding disorders or other bleeding risks or risk of infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02505087


Contacts
Contact: Brigitte ESTOURNET, MD, PhD + 33 (0) 1 47 10 78 90 brigitte.estournet@aphp.fr
Contact: Ana FERREIRO, MD, PhD + 33 (0)1 57 27 79 59 ana.b.ferreiro@gmail.com

Locations
France
UMR8251 University Paris Diderot / CNRS Recruiting
Paris, France, 75013
Contact: ANA FERREIRO, MD, PhD         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Brigitte ESTOURNET, MD, PhD Neuro-Respiratory Rehabilitation Service, Raymond Poincaré Hospital, 92380 Garches, France

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02505087     History of Changes
Other Study ID Numbers: P100152
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: November 21, 2016
Last Verified: November 2016

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Selenoprotein N-related myopathy
biomarkers
washout
N-ACETYLCYSTEINE

Additional relevant MeSH terms:
Muscular Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn
Musculoskeletal Diseases
Nervous System Diseases
Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes